- Published on
Ophthalmology – Conjunctival Primary Acquired Melanosis (PAM)
Conjunctival primary acquired melanosis (PAM) is an acquired, flat pigmentation of the conjunctiva that typically develops in middle-aged or older adults, most often in individuals with lighter skin. It is usually unilateral, nonhereditary, and slowly progressive, and can involve multiple regions of the conjunctiva including the limbus, bulbar surface, fornix, caruncle, and even the tarsal conjunctiva. Unlike conjunctival melanoma, PAM generally lacks prominent vascularity and appears as a patchy, brown discoloration of the ocular surface.
The clinical importance of PAM lies in its potential to act as a precursor to conjunctival melanoma, particularly when atypia is present. Patients often report a gradually enlarging pigmented area on the eye, although many remain asymptomatic. The condition is more common in Caucasians and has been associated with sunlight exposure, though no single definitive risk factor has been identified.
Pathophysiologically, PAM begins as melanocytic proliferation in the basal layer of the conjunctival epithelium. In cases with atypia, these abnormal melanocytes can extend upward through the epithelial layers and eventually penetrate the basement membrane, transforming into invasive melanoma. Histologically, PAM is classified into two main types: without atypia (benign) and with atypia (premalignant). The risk of progression to melanoma is negligible in PAM without atypia but increases significantly with atypia—especially severe atypia, where transformation risk can be very high.
Diagnosis is primarily clinical, supported by careful slit-lamp examination and documentation of lesion extent (often measured in clock hours). Imaging such as anterior segment OCT may help confirm that the lesion is superficial without deeper invasion. In selected cases, biopsy or cytologic evaluation may be performed to assess for atypia, although some clinicians prefer to proceed directly to treatment without prior manipulation.
Management depends on the extent and histologic features of the lesion. Small areas may be observed, especially if atypia is not suspected. More extensive or suspicious lesions are typically treated with surgical excision combined with cryotherapy to surrounding tissue. For diffuse or recurrent disease, topical chemotherapy agents such as mitomycin C may be used, and in extensive cases, even radiotherapy can be considered. The goal is to eliminate abnormal pigmentation and reduce the risk of malignant transformation.
Lifelong follow-up is essential. Patients are usually monitored every 3–4 months initially, then every 6 months once stability is established. Regular examinations focus on detecting growth, recurrence, or transformation into melanoma.
The prognosis is excellent if PAM remains non-atypical. However, once transformation to melanoma occurs, the prognosis becomes more guarded due to the risk of metastasis. Complications from treatment may include ocular surface issues such as dry eye, scarring, symblepharon, and, rarely, vision loss, particularly in advanced or extensively treated cases.
Conjunctival primary acquired melanosis (PAM) is an acquired, flat pigmentation of the conjunctiva that typically develops in middle-aged or older adults, most often in individuals with lighter skin. It is usually unilateral, nonhereditary, and slowly progressive, and can involve multiple regions of the conjunctiva including the limbus, bulbar surface, fornix, caruncle, and even the tarsal conjunctiva. Unlike conjunctival melanoma, PAM generally lacks prominent vascularity and appears as a patchy, brown discoloration of the ocular surface.
The clinical importance of PAM lies in its potential to act as a precursor to conjunctival melanoma, particularly when atypia is present. Patients often report a gradually enlarging pigmented area on the eye, although many remain asymptomatic. The condition is more common in Caucasians and has been associated with sunlight exposure, though no single definitive risk factor has been identified.
Pathophysiologically, PAM begins as melanocytic proliferation in the basal layer of the conjunctival epithelium. In cases with atypia, these abnormal melanocytes can extend upward through the epithelial layers and eventually penetrate the basement membrane, transforming into invasive melanoma. Histologically, PAM is classified into two main types: without atypia (benign) and with atypia (premalignant). The risk of progression to melanoma is negligible in PAM without atypia but increases significantly with atypia—especially severe atypia, where transformation risk can be very high.
Diagnosis is primarily clinical, supported by careful slit-lamp examination and documentation of lesion extent (often measured in clock hours). Imaging such as anterior segment OCT may help confirm that the lesion is superficial without deeper invasion. In selected cases, biopsy or cytologic evaluation may be performed to assess for atypia, although some clinicians prefer to proceed directly to treatment without prior manipulation.
Management depends on the extent and histologic features of the lesion. Small areas may be observed, especially if atypia is not suspected. More extensive or suspicious lesions are typically treated with surgical excision combined with cryotherapy to surrounding tissue. For diffuse or recurrent disease, topical chemotherapy agents such as mitomycin C may be used, and in extensive cases, even radiotherapy can be considered. The goal is to eliminate abnormal pigmentation and reduce the risk of malignant transformation.
Lifelong follow-up is essential. Patients are usually monitored every 3–4 months initially, then every 6 months once stability is established. Regular examinations focus on detecting growth, recurrence, or transformation into melanoma.
The prognosis is excellent if PAM remains non-atypical. However, once transformation to melanoma occurs, the prognosis becomes more guarded due to the risk of metastasis. Complications from treatment may include ocular surface issues such as dry eye, scarring, symblepharon, and, rarely, vision loss, particularly in advanced or extensively treated cases.
0 Comments
